MAP to Provide Access to Eltrombopag, for Treatment of Patients With

Clinical Trial Summary

The purpose of this Cohort Treatment Plan is to allow access to eltrombopag for eligible patients diagnosed with medically significant thrombocytopenia. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04003220` - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Completed	`NCT02948283` - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia	Phase 1
Recruiting	`NCT03633019` - High-dose Use of rhTPO in CIT Patients	Phase 4
Recruiting	`NCT06087198` - Clinical Performance Evaluation of T-TAS®01 HD Chip
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Active, not recruiting	`NCT03688191` - Study of Sirolimus in CTD-TP in China	Phase 4
Completed	`NCT02845609` - Efficacy of Sialic Acid GNE Related Thrombocytopenia	Phase 2
Recruiting	`NCT02244658` - Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia	Phase 3
Recruiting	`NCT02241031` - Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia	Phase 2/Phase 3
Terminated	`NCT01368211` - Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)	Phase 2/Phase 3
Unknown status	`NCT01196884` - Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
Completed	`NCT01356576` - Effect of Hemodialysis Membranes on Platelet Count	N/A
Completed	`NCT00039858` - Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin	Phase 4
Completed	`NCT00787241` - Platelet Count Trends in Pre-eclamptic Parturients	N/A
Completed	`NCT00001533` - Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine	Phase 1
Not yet recruiting	`NCT06036966` - The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients	Phase 2
Completed	`NCT01791101` - Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.	Phase 2
Recruiting	`NCT06053021` - Antiplatelet Therapy for AIS Patients With Thrombocytopenia	N/A
Recruiting	`NCT03701217` - Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML	Phase 2/Phase 3
Not yet recruiting	`NCT05958511` - Assessment of Risk Factors and Outcome of Thrombocytopenia in ICU Patients

NCT number	NCT04837703
Study type	Expanded Access
Source	Novartis
Contact	MAP requests are initiated by a licensed physician.https:// www.
Phone	1-888-669-6682
Email	novartis.email@novartis.com
Status	Available
Phase

MAP to Provide Access to Eltrombopag, for Treatment of Patients With Medically Significant Thrombocytopenia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms